Skip to main content
Top
Published in: European Radiology 11/2019

01-11-2019 | Urogenital

The relationship between adrenal incidentalomas and mortality risk

Authors: Michio Taya, Viktoriya Paroder, Eran Bellin, Linda B. Haramati

Published in: European Radiology | Issue 11/2019

Login to get access

Abstract

Objective

To determine all-cause mortality risk in patients with and without adrenal incidentaloma.

Methods

Retrospective cohort study of patients with CT abdomen performed within 24 h of emergency room presentation at an academic medical center from January 1, 2005, to December 31, 2009, without history of adrenal disease, adrenal lab testing, or cancer. Incidentaloma cohort identified by database query of imaging reports followed by manual review and matched to no-nodule controls at 3:1 on age ± 1 year and exam date ± 3 months. Mortality ascertained by in-hospital deaths and National Death Index query. Survival analysis performed with Kaplan-Meier curves and Cox proportional hazards models.

Results

Among 42,575 adults with abdominal CT exams, 969 adrenal incidentaloma patients and 2907 no-nodule controls were identified. All 3876 individuals entered survival analysis with 31,182 person-years at risk (median follow-up 8.9 years [IQR, 6.9–10.7]). All-cause mortality was significantly higher among those with adrenal incidentalomas (353/969, 36.4%) compared with those without (919/2907, 31.6%; mortality difference 7.6 per 1000 person-years; multivariable-adjusted hazard ratio [aHR] 1.14; 95% CI, 1.003–1.29). Exploratory analyses, limited by missing covariates, found that adrenal incidentalomas were associated with significantly increased incidence of malignancy (aHR 1.61; 95% CI, 1.22–2.12), diabetes (aHR 1.43; 95% CI, 1.18–1.71), heart failure (aHR 1.32; 95% CI, 1.07–1.63), peripheral vascular disease (aHR 1.28; 95% CI, 1.95–1.56), renal disease (aHR 1.21; 95% CI, 1.01–1.44), and chronic pulmonary disease (aHR 1.22; 95% CI, 1.01–1.46) compared with controls.

Conclusions

Adrenal incidentalomas are associated with increased mortality and may represent a clinically valuable biomarker.

Key Points

• Adrenal incidentalomas are associated with increased mortality.
• Adrenal incidentaloma size is not predictive of mortality.
• On exploratory analyses, adrenal incidentalomas are associated with chronic illnesses.
Appendix
Available only for authorised users
Literature
1.
go back to reference Grumbach MM, Biller BM, Braunstein GD et al (2003) Management of the clinically inapparent adrenal mass (“incidentaloma”). Ann Intern Med 138:424–429CrossRef Grumbach MM, Biller BM, Braunstein GD et al (2003) Management of the clinically inapparent adrenal mass (“incidentaloma”). Ann Intern Med 138:424–429CrossRef
2.
go back to reference Young WF Jr (2007) Clinical practice. The incidentally discovered adrenal mass. N Engl J Med 356:601–610CrossRef Young WF Jr (2007) Clinical practice. The incidentally discovered adrenal mass. N Engl J Med 356:601–610CrossRef
3.
go back to reference Song JH, Chaudhry FS, Mayo-Smith WW (2008) The incidental adrenal mass on CT: prevalence of adrenal disease in 1,049 consecutive adrenal masses in patients with no known malignancy. AJR Am J Roentgenol 190:1163–1168CrossRef Song JH, Chaudhry FS, Mayo-Smith WW (2008) The incidental adrenal mass on CT: prevalence of adrenal disease in 1,049 consecutive adrenal masses in patients with no known malignancy. AJR Am J Roentgenol 190:1163–1168CrossRef
4.
go back to reference Hu M, Yip R, Yankelevitz DY, Henschke CI (2016) CT screening for lung cancer: frequency of enlarged adrenal glands identified in baseline and annual repeat rounds. Eur Radiol 26:4475–4481CrossRef Hu M, Yip R, Yankelevitz DY, Henschke CI (2016) CT screening for lung cancer: frequency of enlarged adrenal glands identified in baseline and annual repeat rounds. Eur Radiol 26:4475–4481CrossRef
5.
go back to reference Mayo-Smith WW, Song JH, Boland GL et al (2017) Management of incidental adrenal masses: a white paper of the ACR incidental findings committee. J Am Coll Radiol 14:1038–1044CrossRef Mayo-Smith WW, Song JH, Boland GL et al (2017) Management of incidental adrenal masses: a white paper of the ACR incidental findings committee. J Am Coll Radiol 14:1038–1044CrossRef
6.
go back to reference Berland LL, Silverman SG, Gore RM et al (2010) Managing incidental findings on abdominal CT: white paper of the ACR incidental findings committee. J Am Coll Radiol 7:754–773CrossRef Berland LL, Silverman SG, Gore RM et al (2010) Managing incidental findings on abdominal CT: white paper of the ACR incidental findings committee. J Am Coll Radiol 7:754–773CrossRef
7.
go back to reference Zeiger MA, Thompson GB, Duh QY et al (2009) American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons Medical Guidelines for the management of adrenal incidentalomas: executive summary of recommendations. Endocr Pract 15:450–453CrossRef Zeiger MA, Thompson GB, Duh QY et al (2009) American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons Medical Guidelines for the management of adrenal incidentalomas: executive summary of recommendations. Endocr Pract 15:450–453CrossRef
8.
go back to reference Fassnacht M, Arlt W, Bancos I et al (2016) Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the study of adrenal tumors. Eur J Endocrinol 175:G1–G34CrossRef Fassnacht M, Arlt W, Bancos I et al (2016) Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the study of adrenal tumors. Eur J Endocrinol 175:G1–G34CrossRef
9.
go back to reference Kastelan D, Kraljevic I, Dusek T et al (2015) The clinical course of patients with adrenal incidentaloma: is it time to reconsider the current recommendations? Eur J Endocrinol 173:275–282CrossRef Kastelan D, Kraljevic I, Dusek T et al (2015) The clinical course of patients with adrenal incidentaloma: is it time to reconsider the current recommendations? Eur J Endocrinol 173:275–282CrossRef
10.
go back to reference Cawood TJ, Hunt PJ, O'Shea D, Cole D, Soule S (2009) Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Eur J Endocrinol 161:513–527CrossRef Cawood TJ, Hunt PJ, O'Shea D, Cole D, Soule S (2009) Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Eur J Endocrinol 161:513–527CrossRef
11.
go back to reference Kaltsas G, Chrisoulidou A, Piaditis G, Kassi E, Chrousos G (2012) Current status and controversies in adrenal incidentalomas. Trends Endocrinol Metab 23:602–609CrossRef Kaltsas G, Chrisoulidou A, Piaditis G, Kassi E, Chrousos G (2012) Current status and controversies in adrenal incidentalomas. Trends Endocrinol Metab 23:602–609CrossRef
12.
go back to reference Di Dalmazi G, Vicennati V, Garelli S et al (2014) Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing's syndrome: a 15-year retrospective study. Lancet Diabetes Endocrinol 2:396–405CrossRef Di Dalmazi G, Vicennati V, Garelli S et al (2014) Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing's syndrome: a 15-year retrospective study. Lancet Diabetes Endocrinol 2:396–405CrossRef
13.
go back to reference Morelli V, Reimondo G, Giordano R et al (2014) Long-term follow-up in adrenal incidentalomas: an Italian multicenter study. J Clin Endocrinol Metab 99:827–834CrossRef Morelli V, Reimondo G, Giordano R et al (2014) Long-term follow-up in adrenal incidentalomas: an Italian multicenter study. J Clin Endocrinol Metab 99:827–834CrossRef
14.
go back to reference Debono M, Bradburn M, Bull M, Harrison B, Ross RJ, Newell-Price J (2014) Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas. J Clin Endocrinol Metab 99:4462–4470CrossRef Debono M, Bradburn M, Bull M, Harrison B, Ross RJ, Newell-Price J (2014) Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas. J Clin Endocrinol Metab 99:4462–4470CrossRef
15.
go back to reference Patrova J, Kjellman M, Wahrenberg H, Falhammar H (2017) Increased mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: a 13-year retrospective study from one center. Endocrine 58:267–275CrossRef Patrova J, Kjellman M, Wahrenberg H, Falhammar H (2017) Increased mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: a 13-year retrospective study from one center. Endocrine 58:267–275CrossRef
16.
go back to reference Lopez D, Luque-Fernandez MA, Steele A, Adler GK, Turchin A, Vaidya A (2016) “Nonfunctional” adrenal tumors and the risk for incident diabetes and cardiovascular outcomes: a cohort study. Ann Intern Med 165:533–542CrossRef Lopez D, Luque-Fernandez MA, Steele A, Adler GK, Turchin A, Vaidya A (2016) “Nonfunctional” adrenal tumors and the risk for incident diabetes and cardiovascular outcomes: a cohort study. Ann Intern Med 165:533–542CrossRef
17.
go back to reference Becker J, Woloszyn J, Bold R, Campbell MJ (2018) The adrenal incidentaloma: an opportunity to improve patient care. J Gen Intern Med 33:256 Becker J, Woloszyn J, Bold R, Campbell MJ (2018) The adrenal incidentaloma: an opportunity to improve patient care. J Gen Intern Med 33:256
18.
go back to reference Bellin E, Fletcher DD, Geberer N, Islam S, Srivastava N (2010) Democratizing information creation from health care data for quality improvement, research, and education-the Montefiore Medical Center Experience. Acad Med 85:1362–1368CrossRef Bellin E, Fletcher DD, Geberer N, Islam S, Srivastava N (2010) Democratizing information creation from health care data for quality improvement, research, and education-the Montefiore Medical Center Experience. Acad Med 85:1362–1368CrossRef
19.
go back to reference Bellin E (2017) How to ask and answer questions using electronic medical record data. CreateSpace, North Charleston, South Carolina Bellin E (2017) How to ask and answer questions using electronic medical record data. CreateSpace, North Charleston, South Carolina
20.
go back to reference Bellin E (2015) Riddles in accountable healthcare: a primer to develop analytic intuition for medical homes and population health. CreateSpace, North Charleston, South Carolina Bellin E (2015) Riddles in accountable healthcare: a primer to develop analytic intuition for medical homes and population health. CreateSpace, North Charleston, South Carolina
21.
go back to reference Quan H, Li B, Couris CM et al (2011) Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 173:676–682CrossRef Quan H, Li B, Couris CM et al (2011) Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 173:676–682CrossRef
22.
go back to reference Quan H, Sundararajan V, Halfon P et al (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43:1130–1139CrossRef Quan H, Sundararajan V, Halfon P et al (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43:1130–1139CrossRef
23.
go back to reference Hong AR, Kim JH, Park KS et al (2017) Optimal follow-up strategies for adrenal incidentalomas: reappraisal of the 2016 ESE-ENSAT guidelines in real clinical practice. Eur J Endocrinol 177:475–483CrossRef Hong AR, Kim JH, Park KS et al (2017) Optimal follow-up strategies for adrenal incidentalomas: reappraisal of the 2016 ESE-ENSAT guidelines in real clinical practice. Eur J Endocrinol 177:475–483CrossRef
24.
go back to reference Androulakis II, Kaltsas GA, Kollias GE et al (2014) Patients with apparently nonfunctioning adrenal incidentalomas may be at increased cardiovascular risk due to excessive cortisol secretion. J Clin Endocrinol Metab 99:2754–2762CrossRef Androulakis II, Kaltsas GA, Kollias GE et al (2014) Patients with apparently nonfunctioning adrenal incidentalomas may be at increased cardiovascular risk due to excessive cortisol secretion. J Clin Endocrinol Metab 99:2754–2762CrossRef
25.
go back to reference Akkan T, Altay M, Unsal Y, Dagdeviren M, Beyan E (2017) Nonfunctioning adrenal incidentaloma affecting central blood pressure and arterial stiffness parameters. Endocrine 58:513–520CrossRef Akkan T, Altay M, Unsal Y, Dagdeviren M, Beyan E (2017) Nonfunctioning adrenal incidentaloma affecting central blood pressure and arterial stiffness parameters. Endocrine 58:513–520CrossRef
26.
go back to reference Muscogiuri G, Colao A, Orio F (2015) Insulin-mediated diseases: adrenal mass and polycystic ovary syndrome. Trends Endocrinol Metab 26:512–514CrossRef Muscogiuri G, Colao A, Orio F (2015) Insulin-mediated diseases: adrenal mass and polycystic ovary syndrome. Trends Endocrinol Metab 26:512–514CrossRef
27.
go back to reference Peppa M, Boutati E, Koliaki C et al (2010) Insulin resistance and metabolic syndrome in patients with nonfunctioning adrenal incidentalomas: a cause-effect relationship? Metabolism 59:1435–1441CrossRef Peppa M, Boutati E, Koliaki C et al (2010) Insulin resistance and metabolic syndrome in patients with nonfunctioning adrenal incidentalomas: a cause-effect relationship? Metabolism 59:1435–1441CrossRef
28.
go back to reference Kamio T, Shigematsu K, Kawai K, Tsuchiyama H (1991) Immunoreactivity and receptor expression of insulinlike growth factor I and insulin in human adrenal tumors. An immunohistochemical study of 94 cases. Am J Pathol 138:83–91PubMedPubMedCentral Kamio T, Shigematsu K, Kawai K, Tsuchiyama H (1991) Immunoreactivity and receptor expression of insulinlike growth factor I and insulin in human adrenal tumors. An immunohistochemical study of 94 cases. Am J Pathol 138:83–91PubMedPubMedCentral
29.
go back to reference Ilvesmaki V, Kahri AI, Miettinen PJ, Voutilainen R (1993) Insulin-like growth factors (IGFs) and their receptors in adrenal tumors: high IGF-II expression in functional adrenocortical carcinomas. J Clin Endocrinol Metab 77:852–858PubMed Ilvesmaki V, Kahri AI, Miettinen PJ, Voutilainen R (1993) Insulin-like growth factors (IGFs) and their receptors in adrenal tumors: high IGF-II expression in functional adrenocortical carcinomas. J Clin Endocrinol Metab 77:852–858PubMed
30.
go back to reference Corwin MT, Chalfant JS, Loehfelm TW, Fananapazir G, Lamba R, Mayo-Smith WW (2018) Incidentally detected bilateral adrenal nodules in patients without cancer: is further workup necessary? AJR Am J Roentgenol 210:780–784 Corwin MT, Chalfant JS, Loehfelm TW, Fananapazir G, Lamba R, Mayo-Smith WW (2018) Incidentally detected bilateral adrenal nodules in patients without cancer: is further workup necessary? AJR Am J Roentgenol 210:780–784
31.
go back to reference Derwahl M, Studer H (2002) Hyperplasia versus adenoma in endocrine tissues: are they different? Trends Endocrinol Metab 13:23–28CrossRef Derwahl M, Studer H (2002) Hyperplasia versus adenoma in endocrine tissues: are they different? Trends Endocrinol Metab 13:23–28CrossRef
Metadata
Title
The relationship between adrenal incidentalomas and mortality risk
Authors
Michio Taya
Viktoriya Paroder
Eran Bellin
Linda B. Haramati
Publication date
01-11-2019
Publisher
Springer Berlin Heidelberg
Published in
European Radiology / Issue 11/2019
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-019-06202-y

Other articles of this Issue 11/2019

European Radiology 11/2019 Go to the issue